HEPATITIS C PREVALENCE IN PERINATALLY INFECTED HIV-INFECTED CHILDREN

围产期感染艾滋病毒的儿童中丙型肝炎的患病率

• 批准号: 7376260
• 负责人: RUSSELL B. VAN DYKE
• 金额: $ 0.32万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376260
• 关键词: HEPATITIS; PREVALENCE; PERINATALLY; INFECTED; HIV

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a prevalence study of Hepatitis C Virus (HCV) infection. 600 perinatally-infected HIV-infected children greater than or equal to one year to less than 21 years of age who are enrolled in PACTG 219C will be enrolled in this substudy. A single blood draw for HCV antibody (EnzymeImmunoassay-EIA) testing and HCV RNA (Polymerase Chain Reaction-PCR) testing. One visit for HCV negative subjects; two visits for subjects with positive HCV test results; two or three visits for subjects discordant HCV test results. The primary objective of this study is to determine the prevalence of Hepatitis C in a randomly selected subset of perinatally-infected HIV-positive children enrolled in PACTG 219C. Other objectives are to perform descriptive analyses of possible co-factors in the perinatal transmission of Hepatitis C virus; to perform descriptive analyses of clinical symptoms and liver function tests in subjects found to be HCV-infected; to compare the performance of HCV antibody testing (EIA) and HCV RNA PCR testing in children; and to achieve samples for Hepatitis C virus testing at a future date.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。这是一项丙型肝炎病毒 (HCV) 感染流行率研究。纳入 PACTG 219C 的 600 名大于或等于 1 岁至小于 21 岁的围产期 HIV 感染儿童将被纳入本次研究。一次抽血用于 HCV 抗体（酶免疫分析 - EIA）检测和 HCV RNA（聚合酶链反应 - PCR）检测。 HCV 阴性受试者就诊 1 次；对 HCV 检测结果呈阳性的受试者进行两次就诊；对于 HCV 检测结果不一致的受试者进行两次或三次就诊。本研究的主要目的是确定参加 PACTG 219C 的围产期感染 HIV 阳性儿童中随机选择的丙型肝炎患病率。其他目标是对丙型肝炎病毒围产期传播中可能的辅助因素进行描述性分析；对被发现感染 HCV 的受试者的临床症状和肝功能测试进行描述性分析；比较儿童 HCV 抗体检测 (EIA) 和 HCV RNA PCR 检测的效果；并在未来获得用于丙型肝炎病毒检测的样本。